EUVIMEDEUVIMED entdecken
Open Access

TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice

Noelle E Gillis iD, Lauren M Cozzens, Emily R Wilson, Noah M Smith, Jennifer A Tomczak, Eric L Bolf, Frances E Carr iD

Endocrinology · 2023

DOI: 10.1210/endocr/bqad135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, 2023. Verfasst von Noelle E Gillis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid hormone receptor beta (TRβ) is a recognized tumor suppressor in numerous solid cancers. The molecular signaling of TRβ has been elucidated in several cancer types through re-expression models. Remarkably, the potential impact of selective activation of endogenous TRβ on tumor progression remains largely unexplored. We used cell-based and in vivo assays to evaluate the effects of the TRβ agonist sobetirome (GC-1) on a particularly aggressive and dedifferentiated cancer, anaplastic thyroid cancer (ATC). Here we report that GC-1 reduced the tumorigenic phenotype, decreased cancer stem-like cell populations, and induced redifferentiation of the ATC cell lines with different mutational backgrounds. Of note, this selective activation of TRβ amplified the effects of therapeutic agents in blunting the aggressive cell phenotype and stem cell growth. In xenograft assays, GC-1 alone inhibited tumor growth and was as effective as the kinase inhibitor, sorafenib. These results indicate that selective activation of TRβ not only induces a tumor suppression program de novo but enhances the effectiveness of anticancer agents, revealing potential novel combination therapies for ATC and other aggressive solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Carcinoma, AnaplasticThyroid NeoplasmsFemaleHumansAnimalsMiceThyroid Hormone Receptors betaAcetatesPhenols

Stichwörter der Autor:innen

GC-1anaplastic thyroid cancersobetiromethyroid hormone receptor

Substanzen

Thyroid Hormone Receptors betaGC 1 compoundAcetatesPhenols

Autor:innen und Institutionen

  • Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
  • University of Vermont Cancer Center, University of Vermont, Burlington, VT 05405, USA.

ORCID-Profile: Noelle E Gillis, Frances E Carr

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Gillis, N. E., Cozzens, L. M., Wilson, E. R., Smith, N. M., Tomczak, J. A., Bolf, E. L., & Carr, F. E. (2023). TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice. Endocrinology. https://doi.org/10.1210/endocr/bqad135

Vancouver

Gillis NE, Cozzens LM, Wilson ER, Smith NM, Tomczak JA, Bolf EL, et al. TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice. Endocrinology. 2023. doi:10.1210/endocr/bqad135

BibTeX
@article{Gillis2023,
  author = {Gillis, Noelle E and Cozzens, Lauren M and Wilson, Emily R and Smith, Noah M and Tomczak, Jennifer A and Bolf, Eric L and Carr, Frances E},
  title = {TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice},
  journal = {Endocrinology},
  year = {2023},
  doi = {10.1210/endocr/bqad135}
}
Kostenlos starten →